Market Newsdesk

SAN DIEGO, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) — Maravai LifeSciences Holdings, Inc.(Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the pricing of a public offering of 20,000,000 shares of Maravai’s Class A common stock by certain selling stockholders that was previously announced, at a public offering price of $50.00 per share. In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of Maravai’s Class A common stock. The offering is expected to close on September 14, 2021, subject to customary closing conditions.

Maravai will not receive any proceeds from the sale of shares by the selling stockholders.

Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC are acting as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel and KeyBanc Capital Markets are also acting as joint book-running managers, and Academy Securities, Loop Capital Markets, Penserra Securities LLC and Tigress Financial Partners are acting as co-managers for the offering.

The offering is being made only by means of a prospectus, copies of which may be obtained from: Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at [email protected]; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526, by facsimile at 212-902-9316 or by email at [email protected].

A registration statement relating to the sale of these securities has been filed with, and declared effective by, the Securities and Exchange Commission (the “SEC”) on September 9, 2021. Copies of the registration statement can be accessed by visiting the SEC’s website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologic safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.

Note Regarding Forward-Looking Statements

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following:

• Certain of our products are used by customers in the production of vaccines and therapies, some of which represent relatively new and still-developing modes of treatment. Unforeseen adverse events, negative clinical outcomes, or increased regulatory scrutiny of these vaccines and therapies and their financial cost may damage public perception of the safety, utility, or efficacy of these vaccines and therapies or other modes of treatment and may harm our customers’ ability to conduct their business. Such events may negatively impact our revenue and have an adverse effect on our performance.
• We compete with life science, pharmaceutical and biotechnology companies who are substantially larger than we are and potentially capable of developing new approaches that could make our products, services and technology obsolete.
• We depend on a limited number of customers for a high percentage of our revenue. If we cannot maintain our current relationships with customers, fail to sustain recurring sources of revenue with our existing customers, or if we fail to enter into new relationships, our future operating results will be adversely affected.
• We rely on a limited number of suppliers or, in some cases, sole suppliers, for some of our raw materials and may not be able to find replacements or immediately transition to alternative suppliers.
• Such other factors as discussed throughout the “Risk Factors” section of our Annual Report on Form 10-K filed on March 22, 2021 and our Quarterly Reports on Form 10-Q filed on May 12 and August 11, 2021, respectively, with the SEC.

Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

Contact Information:
Media Contact: Sara Michelmore MacDougall
+1 781-235-3060
[email protected] 

Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
[email protected] 
[email protected]

SAN CARLOS, Calif., Sept. 10, 2021 (GLOBE NEWSWIRE) — Check Point Research, the Threat Intelligence arm of Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, has published its latest Global Threat Index for August 2020. Researchers found that the Qbot trojan, also known as Qakbot and Pinkslipbot, has entered the top ten malware index for the first time, ranking as the 10^th most prevalent malware in August, while the Emotet trojan remains in 1^st place for a second month, impacting 14% of organizations globally.

First seen in 2008, Qbot has been continually developed and now uses sophisticated credentials theft and ransomware installation techniques, making it the malware equivalent of a Swiss Army knife according to researchers. Qbot now also has a dangerous new feature: a specialized email collector module which extracts email threads from the victim’s Outlook client and uploads them to an external remote server. This enables Qbot to hijack legitimate email conversations from infected users, and then spam itself out using those hijacked emails to increase its chances of tricking other users into getting infected. Qbot can also enable unauthorized banking transactions, by allowing its controller to connect to the victim’s computer.

Check Point’s researchers found several campaigns using Qbot’s new strain between March and August 2020, which included Qbot being distributed by the Emotet trojan. This campaign impacted 5% of organizations globally in July 2020.

“Threat actors are always looking at ways to update existing, proven forms of malware and they have clearly been investing heavily in Qbot’s development to enable data theft on a massive scale from organizations and individuals. We have seen active malspam campaigns distributing Qbot directly, as well as the use of third-party infection infrastructures like Emotet’s to spread the threat even further. Businesses should look at deploying anti-malware solutions that can prevent such content reaching end-users and advise employees to be cautious when opening emails, even when they appear to be from a trusted source,” said Maya Horowitz, Director, Threat Intelligence & Research, Products at Check Point.

The research team also warns that “Web Server Exposed Git Repository Information Disclosure” is the most common exploited vulnerability, impacting 47% of organizations globally, followed by “MVPower DVR Remote Code Execution” which impacted 43% of organizations worldwide. “Dasan GPON Router Authentication Bypass (CVE-2018-10561)” is in third place, with a global impact of 37%.

Top malware families


*The arrows relate to the change in rank compared to the previous month.

This month Emotet remains the most popular malware with a global impact of 14% of organizations, closely followed by Agent Tesla and Formbook affecting 3% of organizations each.

1. ↔ Emotet – Emotet is an advanced, self-propagating and modular Trojan. Emotet was originally a banking Trojan, but recently is used as a distributor of other malware or malicious campaigns. It uses multiple methods for maintaining persistence and evasion techniques to avoid detection. In addition, it can be spread through phishing spam emails containing malicious attachments or links.

2. ↑ Agent Tesla – Agent Tesla is an advanced RAT functioning as a keylogger and information stealer , capable of monitoring and collecting the victim’s keyboard input, system clipboard, taking screenshots, and exfiltrating credentials belonging to of a variety of software installed on a victim’s machine (including Google Chrome, Mozilla Firefox and Microsoft Outlook email client). 

3. ↑ Formbook – Formbook is an Info Stealer that harvests credentials from various web browsers, collects screenshots, monitors and logs keystrokes, and can download and execute files according to its C&C orders.

Top exploited vulnerabilities

This month “Web Server Exposed Git Repository Information Disclosure” is the most common exploited vulnerability, impacting 47% of organizations globally, followed by “MVPower DVR Remote Code Execution” which impacted 43% of organizations worldwide. “Dasan GPON Router Authentication Bypass (CVE-2018-10561)” is in third place, with a global impact of 37%.

1. ↑
   Web Server Exposed Git Repository Information Disclosure – An information disclosure vulnerability that has been reported in Git Repository. Successful exploitation of this vulnerability could allow an unintentional disclosure of account information.
2. 
   ↓
   
   MVPower DVR Remote Code Execution – A remote code execution vulnerability that exists in MVPower DVR devices. A remote attacker can exploit this weakness to execute arbitrary code in the affected router via a crafted request.
3. ↑
   Dasan GPON Router Authentication Bypass (CVE-2018-10561) – An authentication bypass vulnerability that exists in Dasan GPON routers. Successful exploitation of this vulnerability would allow remote attackers to obtain sensitive information and gain unauthorized access into the affected system.

Top mobile malware families

This month xHelper is the most popular mobile malware, followed by Necro and Hiddad.

1. xHelper – A malicious application seen in the wild since March 2019, used for downloading other malicious apps and display advertisements. The application can hide itself from the user, and reinstall itself in case it was uninstalled.

2. Necro – Necro is an Android Trojan Dropper. It can download other malware, showing intrusive ads and stealing money by charging paid subscriptions.

3. Hiddad – Hiddad is an Android malware which repackages legitimate apps and then releases them to a third-party store. Its main function is to display ads, but it can also gain access to key security details built into the OS.

Check Point’s Global Threat Impact Index and its ThreatCloud Map is powered by Check Point’s ThreatCloud intelligence, the largest collaborative network to fight cybercrime which delivers threat data and attack trends from a global network of threat sensors. The ThreatCloud database inspects over 2.5 billion websites and 500 million files daily, and identifies more than 250 million malware activities every day.

The complete list of the top 10 malware families in August can be found on the Check Point Blog.

Follow Check Point Research via:

Blog: https://research.checkpoint.com/
Twitter: https://twitter.com/_cpresearch_

About Check Point Research

Check Point Research provides leading cyber threat intelligence to Check Point Software customers and the greater intelligence community. The research team collects and analyzes global cyber-attack data stored on ThreatCloud to keep hackers at bay, while ensuring all Check Point products are updated with the latest protections. The research team consists of over 100 analysts and researchers cooperating with other security vendors, law enforcement and various CERTs.

About Check Point Software Technologies Ltd.

Check Point Software Technologies Ltd. (www.checkpoint.com) is a leading provider of cyber security solutions to governments and corporate enterprises globally.  Check Point’s solutions protect customers from 5^th generation cyber-attacks with an industry leading catch rate of malware, ransomware and advanced targeted threats. Check Point offers a multilevel security architecture, “Infinity Total Protection with Gen V advanced threat prevention”, this combined product architecture defends an enterprise’s cloud, network and mobile devices. Check Point provides the most comprehensive and intuitive one point of control security management system. Check Point protects over 100,000 organizations of all sizes.

MEDIA CONTACT:
                        

Emilie Beneitez Lefebvre                 

Check Point Software Technologies
[email protected] 

INVESTOR CONTACT:   

Kip E. Meintzer

Check Point Software Technologies
[email protected]             

BEIJING, Sept. 10, 2021 (GLOBE NEWSWIRE) — So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced its unaudited financial results for the second quarter ended June 30, 2021.

Second Quarter 2021 Financial Highlights

• Total revenues were RMB451.8 million (US$70.0 million¹), an increase of 37.7% from RMB328.2 million in the same period of 2020 and exceeding the high-end of the Company’s previous guidance of RMB450 million.
• Net income attributable to So-Young International Inc. was RMB57.6 million (US$8.9 million), representing year-over-year growth of 26 times.
• Non-GAAP net income attributable to So-Young International Inc.² was RMB73.7 million (US$11.4 million), an increase of 145.2% from RMB30.1 million in the second quarter of 2020.

Second Quarter 2021 Operational Highlights

• Average mobile MAUs were 10.0 million, an increase of 47.5% from 6.8 million in the second quarter of 2020.
• Total number of users purchasing reservation services were 244.8 thousand, an increase of 43.6% from 170.6 thousand in the second quarter of 2020.
• Number of paying medical service providers on So-Young’s platform were 4,899, an increase of 31.2% from 3,735 in the second quarter of 2020.
• Number of medical service providers subscribing to information services on So-Young’s platform were 2,236, an increase of 8.8% from 2,056 in the second quarter of 2020.
• Aggregate value of medical aesthetic treatment transactions facilitated by So-Young’s platform was RMB1,039.3 million, an increase of 10.6% from RMB939.6 million in the second quarter of 2020.

Mr. Xing Jin, Co-Founder and Chief Executive Officer of So-Young, commented, “We are very pleased to report another quarter of strong growth with total revenues exceeding the high-end of our guidance at RMB451.8 million, up 37.7% year-over-year. Net income attributable to So-Young International Inc. was RMB57.6 million, representing year-over-year growth of 26 times. Non-GAAP net income attributable to So-Young International Inc. reached RMB73.7 million, an increase of 145.2% from the second quarter of 2020. In June, we announced the acquisition of a controlling interest in Wuhan Miracle Laser Systems. The strategic investment will give us a competitive edge in the non-surgical aesthetics segment and generate synergies by integrating Wuhan Miracle’s products into our existing services.”

“In the second quarter, we continued to grow our customer base with the deep knowledge of popular trends that our platform has accumulated over the years. Average mobile MAUs were 10.0 million, up 47.5 percent year-over-year. To meet the explosive demand in non-surgical categories which made up 70% of total online reservation orders during the quarter, we implemented a series of operational measures to strengthen our capabilities. Looking forward, we believe the Chinese medical aesthetics industry is well on track for rapid growth, and we are committed to building So-Young as the most trustworthy medical aesthetics platform in China,” said Mr. Jin.

Mr. Min Yu, Chief Financial Officer of So-Young, commented, “We achieved strong financial results with substantially improved profitability. Thanks to our strong user growth and renowned brand name, the number of paying medical service providers on our platform grew by 31.2% year-over-year to 4,899. We also made great progress in developing more popular categories such as premium dental services. With solid growth as our basis, we will continuously deliver long-term value for our shareholders.”

Second Quarter 2021 Financial Results

Revenues

Total revenues were RMB451.8 million (US$70.0 million), an increase of 37.7% from RMB328.2 million in the same period of 2020. The increase was primarily due to an increase in average revenue per paying medical service provider.

• Information services revenues were RMB360.7 million (US$55.9 million), an increase of 53.8% from RMB234.5 million in the same period of 2020.

• Reservation services revenues were RMB91.1 million (US$14.1 million), a decrease of 2.8% from RMB93.7 million in the same period of 2020.

Cost of Revenues

Cost of revenues were RMB58.8 million (US$9.1 million), an increase of 15.9% from RMB50.7 million in the second quarter of 2020. Cost of revenues included share-based compensation expenses of RMB3.8 million (US$0.6 million) during the second quarter of 2021, compared with RMB6.0 million in the corresponding period of 2020.

Operating Expenses

Total operating expenses were RMB335.4 million (US$51.9 million), an increase of 16.7% from RMB287.4 million in the second quarter of 2020.

• Sales and marketing expenses were RMB206.7 million (US$32.0 million), an increase of 11.6% from RMB185.2 million in the second quarter of 2020. The increase was primarily due to an increase in payroll costs associated with the expansion of marketing employees. Sales and marketing expenses for the second quarter of 2021 included share-based compensation expenses of RMB1.6 million (US$0.2 million), compared with RMB1.6 million in the corresponding period of 2020.

• General and administrative expenses were RMB56.5 million (US$8.8 million), an increase of 13.3% from RMB49.8 million in the second quarter of 2020. The increase was primarily due to an increase in payroll costs associated with the expansion of administrative employees. General and administrative expenses for the second quarter of 2021 included share-based compensation expenses of RMB7.2 million (US$1.1 million), compared with RMB14.2 million in the corresponding period of 2020.

• Research and development expenses were RMB72.1 million (US$11.2 million), an increase of 37.9% from RMB52.3 million in the second quarter of 2020. The increase was primarily attributable to an increase in payroll costs associated with the expansion of research and development employees. Research and development expenses for the second quarter of 2021 included share-based compensation expenses of RMB3.6 million (US$0.6 million), compared with RMB6.2 million in the corresponding period of 2020.

Income Tax Expenses

Income tax expenses was RMB11.1 million (US$1.7 million), compared with RMB2.8 million income tax expense in the same period of 2020. The change was primarily due to an increase in taxable income.

Net income attributable to So-Young International Inc.

Net income attributable to So-Young International Inc. was RMB57.6 million (US$8.9 million), compared with a net income attributable to So-Young International Inc. of RMB2.1 million in the second quarter of 2020.

Non-GAAP net income attributable to So-Young International Inc.

Non-GAAP net income attributable to So-Young International Inc., which excludes the impact of share-based compensation expenses, was RMB73.7 million (US$11.4 million), compared with RMB30.1 million non-GAAP net income attributable to So-Young International Inc. in the same period of 2020.

Basic and Diluted Earnings per ADS

Basic and diluted income per ADS attributable to ordinary shareholders were RMB0.54 (US$0.08) and RMB0.53 (US$0.08), respectively, compared with basic and diluted income per ADS attributable to ordinary shareholders of RMB0.02 and RMB0.02, respectively, in the same period of 2020.

Cash and Cash Equivalents, Restricted Cash and Term Deposits, Term Deposits and Short-Term Investments

As of June 30, 2021, cash and cash equivalents, restricted cash and term deposits, term deposits and short-term investments were RMB2,262.5 million (US$350.4 million), compared with RMB2,676.0 million as of December 31, 2020.

Recent Update

On September 10, 2021, the board of directors of the Company appointed Mr. Xuejian Li, the Company’s chief technology officer, as a director of the Company, effective immediately.

Business Outlook

For the third quarter of 2021, So-Young expects total revenues to be between RMB430 million (US$66.6 million) and RMB450 million (US$69.7 million), representing a 19.6% to 25.1% increase from the same period in 2020. The above outlook is based on the current market conditions and reflects the Company’s preliminary estimates of market and operating conditions, and customer demand, particularly in view of the potential impact of the COVID-19, the effects of which are difficult to analyze and predict, which are all subject to changes.

Non-GAAP Financial Measures

To supplement the financial measures prepared in accordance with generally accepted accounting principles in the United States, or GAAP, this press release presents non-GAAP (loss)/income from operations and non-GAAP net (loss)/income attributable to So-Young International Inc. by excluding share-based compensation expenses from (loss)/income from operations and net (loss)/income attributable to So-Young International Inc., respectively. The Company believes these non-GAAP financial measures are important to help investors understand the Company’s operating and financial performance, compare business trends among different reporting periods on a consistent basis and assess the Company’s core operating results, as they exclude certain expenses that are not expected to result in cash payments. The use of the above non-GAAP financial measures has certain limitations. Share-based compensation expenses have been and will continue to be incurred in the future and are not reflected in the presentation of the non-GAAP financial measures, but should be considered in the overall evaluation of the Company’s results. The Company compensates for these limitations by providing the relevant disclosure of its share-based compensation expenses in the reconciliations to the most directly comparable GAAP financial measures, which should be considered when evaluating the Company’s performance. These non-GAAP financial measures should be considered in addition to financial measures prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, financial measures prepared in accordance with GAAP. Reconciliation of each of these non-GAAP financial measures to the most directly comparable GAAP financial measure is set forth at the end of this release.

Conference Call Information

So-Young’s management will hold an earnings conference call on Friday, September 10, 2021, at 7:30 AM U.S. Eastern Time (7:30 PM on the same day, Beijing/Hong Kong Time). Participants can register for the conference call by navigating to http://apac.directeventreg.com/registration/event/1155918.

Once preregistration has been completed, participants will receive dial-in numbers, an event passcode, and a unique registrant ID.

To join the conference, please dial the number you receive, enter the event passcode followed by your unique registrant ID, and you will be joined to the conference instantly.

A telephone replay will be available two hours after the conclusion of the conference call through 9:59 AM U.S. Eastern Time, September 18, 2021. The dial-in details are:

International:	+61-2-8199-0299
US:	+1-646-254-3697
Passcode:	1155918

Additionally, a live and archived webcast of this conference call will be available at http://ir.soyoung.com.

About So-Young International Inc.

So-Young International Inc. (Nasdaq: SY) (“So-Young” or the “Company”) is the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry. The Company presents users with reliable information through offering high quality and trustworthy content together with a multitude of social functions on its platform, as well as by curating medical aesthetic service providers that are carefully selected and vetted. Leveraging So-Young’s strong brand image, extensive audience reach, trust from its users, highly engaging social community and data insights, the Company is well-positioned to expand both along the medical aesthetic industry value chain and into the massive, fast-growing consumption healthcare service market.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Among other things, the Financial Guidance and quotations from management in this announcement, as well as So-Young’s strategic and operational plans, contain forward-looking statements. So-Young may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about So-Young’s beliefs and expectations, are forward-looking statements. Forward looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: So-Young’s strategies; So-Young’s future business development, financial condition and results of operations; So-Young’s ability to retain and increase the number of users and medical service providers, and expand its service offerings; competition in the online medical aesthetic service industry; changes in So-Young’s revenues, costs or expenditures; Chinese governmental policies and regulations relating to the online medical aesthetic service industry, general economic and business conditions globally and in China; the impact of the COVID-19 pandemic to So-Young’s business operations and the economy in China and elsewhere generally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in the Company’s filings with the Securities and Exchange Commission. All information provided in this press release and in the attachments is as of the date of the press release, and So-Young undertakes no duty to update such information, except as required under applicable law.

For more information, please contact:

So-Young

Investor Relations
Ms. Vivian Xu
Phone: +86-10-8790-2012
E-mail: [email protected]

Christensen

In China
Mr. Eric Yuan
Phone: +86-10-5900-1548
E-mail: [email protected]

In US
Ms. Linda Bergkamp
Phone: +1-480-614-3004
Email: [email protected]

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except for share and per share data)

	As of
	December 31, 2020		June 30, 2021		June 30, 2021
	RMB		RMB		US$
Assets
Current assets:
Cash and cash equivalents	1,127,055		1,148,808		177,928
Restricted cash and term deposits	21,865		29,141		4,514
Trade receivables	52,871		85,796		13,289
Receivables from online payment platforms	16,182		10,125		1,568
Amounts due from related parties	7,764		2,384		369
Term deposits and short-term investments	1,527,088		1,084,587		167,981
Prepayment and other current assets	43,190		93,755		14,521
Total current assets	2,796,015		2,454,596		380,170
Non-current assets:
Long-term investments	166,100		223,753		34,655
Intangible assets	60,029		56,838		8,803
Goodwill	48,500		49,183		7,617
Property and equipment, net	29,830		25,523		3,953
Deferred tax assets	55,520		55,520		8,599
Operating lease right-of-use assets	120,140		105,031		16,267
Other non-current assets	15,878		141,829		21,967
Total non-current assets	495,997		657,677		101,861
Total assets	3,292,012		3,112,273		482,031
Liabilities
Current liabilities:
Taxes payable	60,070		41,101		6,366
Contract liabilities	135,385		121,991		18,894
Salary and welfare payables	95,758		94,372		14,616
Amounts due to related parties	2,404		2,066		320
Accrued expenses and other current liabilities	237,785		297,440		46,068
Operating lease liabilities-current	39,468		38,868		6,020
Total current liabilities	570,870		595,838		92,284
Non-current liabilities:
Operating lease liabilities-non current	93,044		80,141		12,412
Deferred tax liabilities	8,522		7,981		1,236
Total non-current liabilities	101,566		88,122		13,648
Total liabilities	672,436		683,960		105,932
Mezzanine equity
Redeemable non-controlling interests	23,205		20,642		3,197
Total mezzanine equity	23,205		20,642		3,197

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Continued)

 (All amounts in thousands, except for share and per share data, unless otherwise noted)

Shareholders’ equity:
Treasury stock	–			(217,712	)		(33,719	)
Class A Ordinary shares (US$ 0.0005 par value; 750,000,000 shares authorized as of December 31, 2020 and June 30, 2021; 70,212,159 shares issued and outstanding as of December 31, 2020; 70,801,111 and 68,157,419 shares issued and outstanding as of June 30, 2021, respectively)	224			227			35
Class B Ordinary shares (US$ 0.0005 par value; 20,000,000 shares authorized as of December 31, 2020 and June 30, 2021; 12,000,000 shares issued and outstanding as of December 31, 2020 and June 30, 2021)	37			37			6
Additional paid-in capital	2,892,268			2,927,874			453,470
Statutory reserves	10,562			10,562			1,636
Accumulated deficit	(254,228	)		(241,631	)		(37,424	)
Accumulated other comprehensive loss	(52,492	)		(71,686	)		(11,102	)
Total shareholders’ equity	2,596,371			2,407,671			372,902
Total liabilities, mezzanine equity and shareholders’ equity	3,292,012			3,112,273			482,031

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except for share and per share data)

	For the Three Months Ended									For the Six Months Ended
	June 30, 2020			June 30, 2021			June 30, 2021			June 30, 2020			June 30, 2021			June 30, 2021
	RMB			RMB			US$			RMB			RMB			US$
Revenues
Information services	234,512			360,714			55,867			360,524			638,547			98,898
Reservation services	93,708			91,131			14,115			150,250			172,943			26,786
Total revenues	328,220			451,845			69,982			510,774			811,490			125,684
Cost of revenues	(50,744	)		(58,807	)		(9,108	)		(93,843	)		(111,161	)		(17,217	)
Gross profit	277,476			393,038			60,874			416,931			700,329			108,467
Operating expenses:
Sales and marketing expenses	(185,182	)		(206,730	)		(32,018	)		(294,299	)		(449,088	)		(69,555	)
General and administrative expenses	(49,849	)		(56,494	)		(8,750	)		(83,804	)		(111,671	)		(17,296	)
Research and development expenses	(52,325	)		(72,132	)		(11,172	)		(95,122	)		(141,935	)		(21,983	)
Total operating expenses	(287,356	)		(335,356	)		(51,940	)		(473,225	)		(702,694	)		(108,834	)
(Loss)/income from operations	(9,880	)		57,682			8,934			(56,294	)		(2,365	)		(367	)
Other income/(expenses):
Investment income	2,814			3,064			475			5,789			5,732			888
Interest income	11,785			4,771			739			25,377			10,771			1,668
Exchange (losses)/gains	(27	)		358			55			36			(4,353	)		(674	)
Share of (losses)/income of equity method investee	(1,395	)		54			8			(3,147	)		133			21
Others, net	1,619			1,499			232			(7,026	)		6,904			1,069
Income/(Loss) before tax	4,916			67,428			10,443			(35,265	)		16,822			2,605
Income tax (expenses)/benefit	(2,776	)		(11,122	)		(1,723	)		1,522			(6,788	)		(1,051	)
Net income/(loss)	2,140			56,306			8,720			(33,743	)		10,034			1,554
Net loss attributable to noncontrolling interests	–			1,288			199			–			2,563			397
Net income/(loss) attributable to So-Young International Inc.	2,140			57,594			8,919			(33,743	)		12,597			1,951

SO-YOUNG INTERNATIONAL INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS
(Continued)

(Amounts in thousands, except for share and per share data)

	For the Three Months Ended									For the Six Months Ended
	June 30, 2020			June 30, 2021			June 30, 2021			June 30, 2020			June 30, 2021			June 30, 2021
	RMB			RMB			US$			RMB			RMB			US$
Net income/(loss) per ordinary share
Net earnings/(loss) per ordinary share attributable to ordinary shareholder – basic	0.03			0.70			0.11			(0.42	)		0.15			0.02
Net earnings/(loss) per ordinary share attributable to ordinary shareholder – diluted	0.03			0.69			0.11			(0.42	)		0.15			0.02
Net earnings/(loss) per ADS attributable to ordinary shareholders – basic (13 ADS represents 10 Class A ordinary shares)	0.02			0.54			0.08			(0.32	)		0.12			0.02
Net earnings/(loss) per ADS attributable to ordinary shareholders – diluted (13 ADS represents 10 Class A ordinary shares)	0.02			0.53			0.08			(0.32	)		0.12			0.02
Weighted average number of ordinary shares used in computing earnings/(loss) per share, basic*	81,489,978			82,403,282			82,403,282			81,303,153			82,260,972			82,260,972
Weighted average number of ordinary shares used in computing earnings/(loss) per share, diluted*	83,677,136			83,023,318			83,023,318			81,303,153			83,695,653			83,695,653
Share-based compensation expenses included in:
Cost of revenues	(5,986	)		(3,791	)		(587	)		(8,196	)		(8,124	)		(1,258	)
Sales and marketing expenses	(1,583	)		(1,550	)		(240	)		(2,303	)		(3,844	)		(595	)
General and administrative expenses	(14,198	)		(7,246	)		(1,122	)		(22,535	)		(14,414	)		(2,232	)
Research and development expenses	(6,172	)		(3,564	)		(552	)		(9,167	)		(8,680	)		(1,344	)

   * Both Class A and Class B ordinary shares are included in the calculation of the weighted average number of ordinary shares outstanding, basic and diluted.

SO-YOUNG INTERNATIONAL INC.

Reconciliation of GAAP and Non-GAAP Results

(Amounts in thousands, except for share and per share data)

	For the Three Months Ended							For the Six Months Ended
	June 30, 2020			June 30, 2021		June 30, 2021		June 30, 2020			June 30, 2021			June 30, 2021
	RMB			RMB		US$		RMB			RMB			US$
GAAP (loss)/income from operations	(9,880	)		57,682		8,934		(56,294	)		(2,365	)		(367	)
Add back: Shared-based compensation expenses	27,939			16,151		2,501		42,201			35,062			5,429
Non-GAAP income/(loss) from operations	18,059			73,833		11,435		(14,093	)		32,697			5,062
GAAP Net income/(loss) attributable to So-Young International Inc.	2,140			57,594		8,919		(33,743	)		12,597			1,951
Add back: Shared-based compensation expenses	27,939			16,151		2,501		42,201			35,062			5,429
Non-GAAP Net income attributable to So-Young International Inc.	30,079			73,745		11,420		8,458			47,659			7,380

¹ This press release contains translations of certain Renminbi (RMB) amounts into U.S. dollars (US$) solely for the convenience of the reader. Unless otherwise specified, all translations of Renminbi amounts into U.S. dollar amounts in this press release are made at RMB6.4566 to US$1.00, which was the U.S. dollars middle rate announced by the Board of Governors of the Federal Reserve System of the United States on June 30, 2021.

² Non-GAAP net income attributable to So-Young International Inc. is defined as net income attributable to So-Young International Inc. excluding share-based compensation expenses. See “Reconciliation of GAAP and Non-GAAP Results” at the end of this press release.